Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127329571 | 12732957 | 1 | I | 20160731 | 20160912 | 20160912 | EXP | JP-ASTRAZENECA-2016SE84603 | ASTRAZENECA | 79.00 | YR | F | Y | 38.00000 | KG | 20160912 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127329571 | 12732957 | 1 | PS | IRESSA | GEFITINIB | 1 | Oral | U | 206995 | 250 | MG | TABLET | QD | ||||||
| 127329571 | 12732957 | 2 | SS | IRESSA | GEFITINIB | 1 | Oral | U | 206995 | 250 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127329571 | 12732957 | 1 | Lung adenocarcinoma |
| 127329571 | 12732957 | 2 | Lung adenocarcinoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127329571 | 12732957 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127329571 | 12732957 | Diarrhoea | |
| 127329571 | 12732957 | Haematuria | |
| 127329571 | 12732957 | Malignant neoplasm progression |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127329571 | 12732957 | 1 | 2014 | 0 |